New hope for advanced breast cancer patients in asia after multiple failed chemotherapies
NCT ID NCT04639986
Summary
This study is testing a new drug called sacituzumab govitecan against standard chemotherapy options chosen by doctors. It is for Asian patients with a specific type of advanced breast cancer that has spread and has not responded to at least two prior chemotherapy treatments. The main goal is to see if the new drug can better control the cancer and help patients live longer without their disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Affiliated Tumor Hospital of Xinjiang Medical University
Ürümqi, China
-
Ajou University Hospital
Suwon, South Korea
-
Anhui Provincial Hospital
Hefei, China
-
Asan Medical Center
Seoul, South Korea
-
Cancer Hospital Chinese Academy of Medical Science
Beijing, China
-
Chang Gung Memorial Hospital, Linkou
Taoyuan District, Taiwan
-
Changhua Christian Medical Foundation Changhua Christian Hospital
Changhua, Taiwan
-
China Medical University Hospital
Taichung, Taiwan
-
Chinese PLA General Hospital
Beijing, China
-
Chongqing University Cancer Hospital
Chengdu, China
-
Dong-A University Hospital
Busan, South Korea
-
Fujian Medical University Union Hospital
Fuzhou, China
-
Guangdong Provincial People's Hospital
Guangzhou, China
-
Henan Cancer Hospital
Zhengzhou, China
-
Hubei Cancer Hospital
Wuhan, China
-
Jiangsu Province Hospital
Nanjing, China
-
Jilin Cancer Hospital
Changchun, China
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
-
Korea University Anam Hospital
Seoul, South Korea
-
Linyi Cancer Hospital
Linyi, China
-
Nanjing Drum Tower Hospital
Nanjing, China
-
National Cheng Kung University Hospital
Tainan, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
-
Peking University People's Hospital
Beijing, China
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Seongnam, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, South Korea
-
Shandong Cancer Hospital
Jinan, China
-
Shanghai General Hospital
Shanghai, China
-
Sir Run run Shaw hospital Zhejiang University School of Medicine
Hangzhou, China
-
Sun Yat Sen Memorial Hospital of Sun Yat sen University
Guangzhou, China
-
Sun Yat-sen University Cancer Center
Guangzhou, China
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
-
The First Hospital of Jilin University
Changchun, China
-
The second Hospital of Anhui Medical University
Hefei, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
-
Tri-Service General Hospital
Taipei, Taiwan
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
-
West China Hospital, Sichuan University
Chengdu, China
-
Yunnan Cancer Hospital
Kunming, China
-
Zhejiang Cancer Hospital
Hangzhou, China
Conditions
Explore the condition pages connected to this study.